EXACTA · UNITED STATES
Circulating tumor-associated cell drug-response study
Crook T and colleagues • Cancer Chemotherapy and Pharmacology • online 2020; volume 2021
- DOI
- 10.1007/s00280-020-04189-8
- Design
- Exploratory analyses of laboratory drug response and clinical concordance.
- Population
- 5,090 patients overall; clinical outcome comparisons used smaller subsets.
- Endpoints
- Concordance between circulating-cell and tissue-cell responses, and between laboratory findings and observed treatment response or failure.
- Reported results
- Reported concordance was 93.7% in the 230-patient tissue comparison; 87% in a 143-patient treatment-failure subset; and 97% in a 77-patient treatment-response subset.
- Limitations
- The clinical concordance percentages do not describe all 5,090 patients. Concordance is not proof that test-directed care improves survival.
- Funding and conflicts
- Self-funded by Datar Cancer Genetics; four authors reported full-time sponsor employment.